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1. Introduction
Surgery is the only certain treatment for gastric carcinoma, so early detection and accurate
staging is a key to successive treatment and mortality reduction. In this chapter, we would
like to explain radiologic imaging of gastric carcinoma by
1. Reviewing the evidences for gastric carcinoma screening
2. Demonstrating the TNM classification of gastric carcinoma and the relevant imaging
findings for each stages and
3. Introducing unusual imaging findings of gastric carcinoma and differential diagnoses.
1.1. Gastric carcinoma screening
Gastric carcinoma is the fourth most common cancer worldwide, behind lung, breast and
colorectal carcinomas, and is the second leading cause of death in both sexes worldwide and
in Asia [1, 2]. There is about twice male predominance.Gastric carcinoma is particularly
common in countries such as Korea (incidence 62.2 per 100,000 males; mortality 22.8 per
100,000 males), Japan (46.8; 20.5), China (41.3; 30.5), Chile (27.3; 23.1), Russia (26.9; 24.0) but
not as common in a large part of western societies such as the United States (5.7; 2.7) and
United Kingdom (8.0; 4.8) [1].
The high mortality is mainly due to late presentation, therefore early detection and treat‐
ment is an important way to reduce death from gastric cancer [2].There are four major meth‐
ods for screening gastric carcinoma; fluoroscopy, endoscopy, serum pepsinogen testing, and
Helicobacter pylori antibody testing [3]. Because of a large difference in burden of gastric car‐
cinoma among nations, benefit of gastric cancer screening cannot be debated on the same
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ground for societies throughout the world. However, there have been no randomized trials
evaluating the impact of screening on mortality from gastric carcinoma [2,3].For societies
where gastric carcinoma is uncommon, National Cancer Institute of the United States state
that for screening would not result in a decrease in mortality fromgastric carcinoma [4].
In Japan, there is a government-sponsored mass screening program with barium meal fluo‐
rography. Participants are recommended to undergo endoscopy of the upper gastrointesti‐
nal tract when positive findings are detected at fluorography. Asymptomatic individuals
older than 40 years are eligible for this program, but only around 20% of the eligible subjects
actually participates the program [3]. Most case-control studies from Japan show a 40-60%
decrease in mortality from gastric carcinoma in the subjects who participated the program
[2,5-8]. In contrast, Japanese prospective series setting death from gastric cancer as an end‐
point have inconsistent results [2,9-13].Even in combination with serum pepsinogen, a large
Japanese study screening 17,647 men aged 40-60 years the positive predictive value over the
7-year period was 0.85% [14].Thus even in societies with high incidence, identification of
high-risk groups that benefit from screening may be necessary to perform cost-effective
screening.The subgroups might include elderly patients with atrophic gastritis or pernicious
anemia, patients with partial gastrectomy, patients with Epstein-Barr virus associated gas‐
tric carcinoma or history of multiple carcinomas, patients with the diagnosis of sporadic ad‐
enomas, familial adenomatous polyposis or hereditary nonpolyposis colon cancer [15-19].
Endoscopy has advantage over fluoroscopy, especially in detection of flat and non-ulcera‐
tive lesions. A Japanese study comparing finding ratio of gastric carcinoma with fluorosco‐
py and endoscopy reports 2.7 to 4.6-times higher ratio for endoscopy [20]. However,
effective screening with endoscopy relies on the skill of the endoscopists and availability of
endoscopes, and it is likely to be unfeasible to perform mass screening using endoscopy.
2. TNM classification of gastric carcinomas and the relevant imaging
findings
Owing to recent advances in CT technology, we have been able to visualize early carcino‐
mas and to stage tumors with considerable accuracy, with the use of appropriate contrast
technique and effervescent agent or water [21]. Recent CT with conventional transverse im‐
ages, multiplanar reconstruction (MPR) images and virtual endoscopy can detect gastric car‐
cinomas efficiently with the detection rates of 91%, 96% and 98%, respectively [22].
Gastric carcinomas appear as a focal area of mural thickening with or without ulceration, as
a polypoid lesion, or as generalized mural thickening. Lesions occurring in the antrum, in
the body, and in the fundus comprise 30% of all gastric carcinomas respectively, and the re‐
maining 10% involve the whole stomach [23].
CT criteria for T staging of gastric carcinoma is as follows [22].
T1 lesion = focal thickening of the inner layer, almost well enhanced, and has visible low-
attenuation-strip outer layer of gastric wall and clear fat plane around tumor
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T2 lesion = focal or diffuse thickening of the wall with transmural enhancement, almost well
enhanced, and has smooth outer wall border and clear fat plane around tumor
T3 lesion = transmural tumor with irregular or nodular outer border and/or perigastric fat
infiltration
T4 lesion = Obliteration of fat plane betweengastric tumor and adjacent organ or invasion of
adjacent organ
Figure 1. T1a gastric carcinoma in a 76-year old man. Contrast CT shows a subtle thickening and enhancement of the
inner layer (arrow) with low-attenuation-strip outer layer of gastric wall and clear fat plane around tumor.
Figure 2. T2 gastric carcinoma in a 82-year old man. Contrast CT shows a well-enhanced focal mural thickening (ar‐
row)andfocal enhancement of the outer layer (arrowhead).The tumor has smooth outer wall border and clear fat
plane around tumor.
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Accuracy of CT in T-staging with transverse images only is 73%, but it rises to 89% with the
use of MPR [22]. Therefore it is important to perform appropriate reconstruction techniques
in CT diagnosis of gastric carcinoma.
Figure 3. T3 gastric carcinoma in a 64-year old woman. Contrast CT shows a mass in the lesser curvature (arrow), oblit‐
erating the outer layer of the stomach. The outer border of the tumor is irregular, and perigastric fat stranding is vi‐
sualized (arrowhead).
Figure 4. Type IV gastric carcinoma in a 47-yer old man. Contrast CT shows diffuse mural thickening obliterating the‐
folds and the inner structure of the gastric wall (arrows). The enhancement “running” through the gastric wall is char‐
acteristic of scirrhous tumors.
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T1 tumors are classified into T1a and T1b tumors; a T1a lesion stay within the mucosal layer,
while a T1b lesion stay within the submucosal layer (Figure 1).
A T2 tumor infiltrates into the muscularis propria layer and stays within the layer (Figure 2).
A T3 tumor extends over the muscularis propria layer, but its border stays within the sub‐
serosal layer (Figure 3).
Figure 5. Advanced gastric carcinoma in a 60-year old man. Contrast CT shows diffuse mural thickening of the antrum
(arrows). The fat plane between the tumor and the liver is obliterated. Liver metastasis can be found as well (curved
arrow).
Figure 6. Advanced gastric carcinoma in a 60-year old man (the same patient as Figure 5). The clear and smooth bor‐
der between the tumor and the liver (between two arrows) can be shown with coronal MPR. This tumor can be staged
as T4a.
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T4 tumors are classified into T4a and T4b tumors; A T4a lesion invades the serosa, exposing
its surface to the peritoneal cavity in many cases. The tumor is classified as T4b when it in‐
vades the adjacent organs, such as the transverse colon, pancreas, spleen, liver and the dia‐
phragm.Signet-ring cell carcinoma, often found at T4a stage, usually manifests as a
scirrhous tumor, and appears as diffuse thickening of the gastric wall with obliteration of
gastric folds, usually extending from the antrum into the body and fundus (Figure 4) [23].
T4b tumor requires resection of adjacent organs with the primary tumor, and discrimination
of T4a tumors from “T4b-looking tumor” is an important function of preoperative imaging.
An advanced tumor can be recognized as T4a when the fat plane between the tumor and the
adjacent organ is visualized, or when the fat plane is invisible or compressed by the tumor,
the tumor is considered to be T4a if it has a clear and smooth border (Figures 5-7).MPR in
appropriate plane is especially effective in differentiating between T4a and T4b; MPR is re‐
ported to improve the specificity without compensation in sensitivity in diagnosis of inva‐
sion into the transverse colon or mesocolon and the pancreas [24].
Figure 7. Advanced gastric carcinoma in a 88-year old woman. The tumor extends downwards toward the pancreas
(arrow), and causes dilatation of the main pancreatic duct as a result of pancreatic infiltration (arrowheads). This tu‐
mor is staged as T4b.
Criteria for N staging for gastric carcinoma is as follows:
N0 = no lymph nodes involved
N1 = metastases in 1-2 regional lymph nodes
N2 = metastases in 3-6 regional lymph nodes
N3a = metastases in 7-15 regional lymph nodes
N3b = metastases in more than 15 regional lymph nodes
Gastric carcinoma is often accompanied with nodal metastases even at relatively earlier stages.
Micrometastases and normal-sized metastatic nodes are common in gastric carcinoma, and
this makes accurate N staging difficult. Ring enhancement,inhomogeneous enhancementand
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strong enhancement at arterial phase are known as possible signs of metastases in a normal
sized lymph node. Therefore it is important to point out nodes with these atypical findings,
even when the node is smaller than 10mm.Since accurate counting of lymph node metastases is
the key to accurate N staging,active reconstruction with MPR is warranted for accurate meas‐
urement and interpretation of conglomerated lymph nodes (Figures 8,9).
Figure 8. A 50-year old man with gastric carcinoma. Contrast CT shows a mass at the lesser curvature (arrow).
Figure 9. A 50-year old man with gastric carcinoma (the same patient as Figure 8). MPR in the coronal plane shows
this mass consists of two lymph nodes.
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The liver is the most common metastatic sites for gastric carcinoma because the gastric veins
drain into the hepatic portal system.Metastatic hepatic tumors are often accompanied with
ring enhancement at earlier phase, and portal phase in addition to the equilibrium phase.
Some tumors lose contrast to the liver parenchyma after the delivery of the contrast materi‐
al, and we obtain the plane CT images as well in the metastasis survey protocolof our insti‐
tution.Other common sites for distant metastases include the lungs, adrenal glands, and the
ovaries (Krukenberg tumors).Positron emission tomography (PET) with 2-[fluorine-18]fluo‐
ro-2-deoxy-d-glucose (FDG) is not appropriated for local tumor staging, but is effective for
detection of distant metastases [25].
CT does not have enough sensitivity for detection of peritoneal dissemination. Even with re‐
cent 16- or 64-row detector scanners, the sensitivity and specificity of CT diagnosis of perito‐
neal dissemination are 28.3% and 98.9% respectively when definite criteria are adopted, and
50.9% and 96.2% when the criteria included the suspicious findings [26]. This report men‐
tions greater tumor size and advanced T stage as predictive factors for dissemination, and
recommends staging laparoscopy for tumors with these factors, even when CT results are
negative for peritoneal dissemination. The value of FDG-PET in detection of peritoneal dis‐
semination is still controversial [25].
3. Unusual imaging findings of gastric carcinoma and differential
diagnoses
Rarely, gastric carcinomas present with gross or psammomatous calcifications. Calcified
gastric carcinomas are usually found in mucinous adenocarcinoma; a carcinoma character‐
ized by prominent glandular formations and abundant mucin deposition. Calcifications in
mucinous carcinoma are military and punctate [27,28]. Rarely, calcification within gastric
carcinoma lesion occurs as a result of secretion of parathyroid hormone-like substance [29].
Other reported atypical features of gastric carcinomas include transpyloric spread, giant
gastric folds and hypervascular masses [27,30,31].
Epstein-Barr virus associated gastric carcinoma (EBVaGC) is a clinicopathologically and mo‐
lecularly distinct type of gastric carcinoma.EBV-associated gastric carcinoma (EBVaGC) oc‐
curs worldwide, with the reported incidence varying from 1.3% to 20.1%, affects
70,000-80,000 people per year (estimate), constituting the largest group of EBV-associated
malignancies [16,32,33].EBVaGC is associated with male predominance, location in the prox‐
imal stomach, multiplicity and carcinomas affecting remnant stomachs [33,34].Although
there are some conflicting evidences, lower rate of lymph node involvement and relatively
favorable prognosis is suggested [32,33,35].EBVaGC is associated with two types of histolo‐
gy: lymphoepithelioma (LE) -like type which is almost identical to the subgroup reported as
“gastric carcinoma with lymphoid stroma (GCLS)”, and ordinary type [36,37].Imaging find‐
ings of LE-like type or GCLS is characterized by a large thickness-to-length ratio, and is
sometimes accompanied with a bulky portion projecting from the gastric wall [38] (Figure
10).
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Figure 10. LE-type EBVaGC in a 69-year old woman. Contrast CT shows massive mural thickening involving the gastric
fundus and the esophagogastric junction (arrows).
Gastric carcinoma need to be differentiated from other malignant tumors involvingthe stom‐
ach, whichincludes carcinoid, carcinosarcoma, lymphoma, mucosa-associated lymphoid tis‐
sue lymphoma (MALToma) and gastrointestinal stromal tumor (GIST) (Figures 11-13) [27].
Benign tumors of the stomach include hyperplastic or adenomatous polyps, leiomyoma,
schwannoma, lipoma, hemangioma and glomus tumor. Heterotopic pancreas can also be
mistaken as a gastric carcinoma (Figure 14).
Figure 11. Diffuse large B-cell lymphoma in a 73-year old woman. Contrast CT shows a dumbbell-shaped mass ex‐
tending from the fundus into the spleen (arrow).
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Figure 12. High-grade GIST in a 53-year old man. Contrast CT shows an enormous tumor extending along the outer
gastric wall (arrows).The tumor has a smooth border but the enhancement is very heterogeneous, with a large area of
necrosis showing homogeneous low attenuation. Note the compressed cavity of the stomach (arrowhead).
Figure 13. Low-grade GIST in a 74-year old man. Contrast CT shows a smooth round tumor with homogeneous en‐
hancement within the fundus (arrow).
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Figure 14. A 46-year old woman with a submucosal mass. Contrast CT shows a mass (arrow) presenting similar en‐
hancement as the pancreas (arrowhead). Heterotopic pancreas was suspected on CT and at endoscopic ultrasonogra‐
phy, and was confirmed by fine-needle biopsy.
4. Conclusion
Although early detection is the key to the mortality reduction of gastric carcinoma, the benefit
of screening is still under debate even in the societies with high incidence. Recent CT with ap‐
propriate reconstruction technique can detect and locally stage gastric carcinomas sufficient‐
ly.  It  remains  a  challenge to  accurately  diagnose  lymph node metastasis  and peritoneal
dissemination with imaging. Imaging can also depict unusual manifestationsof gastric carci‐
nomas such as calcification and a large thickness-to-width ratio or projecting mass in EBVaGC.
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